Weekly Recap | Merck +12.3%, closing in on record highs
I'm LongbridgeAI, I can summarize articles.Merck surged 12.3% this week to close at $152.55, leaving the S&P 500 far behind, which fell 1.43% — a gap of roughly 13.7 percentage points. The week started quietly, with the stock drifting between $134 and $137 on Monday and Tuesday on moderate volume. Wednesday (19 August) was the turning point: shares gapped higher and saw 32.8m shares change hands, nearly double the weekly average, peaking at $153.50 before settling at $152.20, up 12.6% on the day. A mild pullback to $148.
The Week
Merck surged 12.3% this week to close at $152.55, leaving the S&P 500 far behind, which fell 1.43% — a gap of roughly 13.7 percentage points. The week started quietly, with the stock drifting between $134 and $137 on Monday and Tuesday on moderate volume. Wednesday (19 August) was the turning point: shares gapped higher and saw 32.8m shares change hands, nearly double the weekly average, peaking at $153.50 before settling at $152.20, up 12.6% on the day. A mild pullback to $148.99 on Thursday was followed by renewed buying on Friday, with the stock closing at $152.55, near the top of the week’s range.
Key Events
The defining moment came before Wednesday’s open, when Moderna and Merck reported positive Phase III results for their personalised mRNA cancer vaccine in melanoma. Merck shares jumped more than 12% on the day, with some call options posting gains of over 500x. The 50⁄50 partnered programme’s success validates the extension of mRNA technology from infectious disease into oncology, and it dialled down the market’s persistent anxiety over Keytruda’s coming patent cliff.
While Moderna subsequently whipsawed — rocketing 177% on Wednesday, then giving back a chunk of those gains on Thursday and Friday — Merck’s move was relatively measured. The stock added another leg higher on Friday. Brokers widely welcomed the trial readout; BMO Capital reiterated its buy rating on Merck. Ripples spread through the biopharma complex, lifting names like BioNTech and Tempus AI, hinting at a rotation within the sector.
Analyst Ratings
Twenty-eight analysts cover Merck: 15 rate it a buy, 5 overweight, and 8 hold, with no underweight or sell ratings. The consensus recommendation is ‘buy’, and the consensus target price sits at $147.77, about 3.1% below Friday’s close. The range is wide, however — from a high of $186.00 to a low of $105.00 — suggesting genuine disagreement about the stock’s long-term value. Ranked against 201 peers in the pharmaceutical industry, Merck’s rating stands at 4th place, near the top tier.
The Week Ahead
No Merck-specific events are on the calendar for next week. The focus shifts to macro data on Tuesday (25 August): FHFA house prices, the Case Shiller 20-city index, consumer confidence, and new home sales will all offer fresh clues on the economy’s resilience and the rate outlook. For Merck, the key question is whether Moderna’s volatility subsides and whether further details from the Phase III data — subgroup analyses or regulatory commentary — surface.
In Short
A powerful catalyst in the form of a cancer vaccine breakthrough drove Merck to a double-digit weekly gain, while the broader market slipped. The analyst community is broadly constructive, with over 70% of ratings in the buy or overweight camp, though the consensus target now trails the share price, suggesting much of the optimism is already priced in. The latest session’s flow data showed large-lot money as a net seller, while retail and mid-size orders were more active. The question ahead is whether this event-driven rally can hold its ground without a fresh catalyst, and whether incoming macro data shifts flows within defensive sectors.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.